Portal de investigación
Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Koreth, John
- Munoz, Maria Carmen Martinez
- Pantin, Jeremy
- Arslan, Shukaib
- Loren, Alison
- Rambaldi, Benedetta
- Sala, Elisa
- Shimoni, Avichai
- Zuckerman, Tsila
- Cutler, Corey
- Acevedo, Lisette
- Phenis, Kham
- Sun, Eugene
- Connelly, Stephen
- Rothman, Joel
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- 274-275
- Factor de Impacto:
- 4,834 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Cita
Koreth,J,Munoz,MCM,Pantin,J,Arslan,S,Sanz,J,Loren,A,Rambaldi,B et al. Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease. 67th Annual Meeting of the American-Society-of-Hematology (ASH). 2025. Orlando. RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2025 p.p. 274-275.